Literature DB >> 28074294

[Procedures on patients receiving NOACs : What's possible?]

A Polzin1, M Kelm2, P Horn2.   

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used in patients with deep vein thrombosis (DVT), pulmonary embolism (PE) and atrial fibrillation (AF). However, there is insufficient data concerning the periinterventional, perioperative, and intensive care management of patients on NOACs. Therefore, the recommendations regarding this management rely on pharmacokinetics of the particular NOAC in combination with the individual patient's characteristics, bleeding risk of the planned intervention/surgery, and urgency of the procedure. This review summarizes evidence and recommendations regarding the optimal periinterventional/perioperative antithrombotic management of patients on NOACs.

Entities:  

Keywords:  Anticoagulants; Bleeding; Intensive care; Perioperative care; Pharmacokinetics

Mesh：

Substances：

Year:  2017        PMID： 28074294     DOI： 10.1007/s00063-016-0239-8

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN： 2193-6218            Impact factor:   0.840


  38 in total

Review 1.  Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.

Authors:  Menno V Huisman; Gregory Y H Lip; Hans-Christoph Diener; Martina Brueckmann; Joanne van Ryn; Andreas Clemens
Journal:  Thromb Haemost       Date:  2012-02-08       Impact factor: 5.249

2.  Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.

Authors:  Jan Beyer-Westendorf; Kati Förster; Sven Pannach; Franziska Ebertz; Vera Gelbricht; Christoph Thieme; Franziska Michalski; Christina Köhler; Sebastian Werth; Kurtulus Sahin; Luise Tittl; Ulrike Hänsel; Norbert Weiss
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

3.  Pacemaker or defibrillator surgery without interruption of anticoagulation.

Authors:  David H Birnie; Jeff S Healey; George A Wells; Atul Verma; Anthony S Tang; Andrew D Krahn; Christopher S Simpson; Felix Ayala-Paredes; Benoit Coutu; Tiago L L Leiria; Vidal Essebag
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

4.  Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS).

Authors:  Gregory Y H Lip; Stephan Windecker; Kurt Huber; Paulus Kirchhof; Francisco Marin; Jurriën M Ten Berg; Karl Georg Haeusler; Giuseppe Boriani; Davide Capodanno; Martine Gilard; Uwe Zeymer; Deirdre Lane; Robert F Storey; Hector Bueno; Jean-Philippe Collet; Laurent Fauchier; Sigrun Halvorsen; Maddalena Lettino; Joao Morais; Christian Mueller; Tatjana S Potpara; Lars Hvilsted Rasmussen; Andrea Rubboli; Juan Tamargo; Marco Valgimigli; Jose L Zamorano
Journal:  Eur Heart J       Date:  2014-08-25       Impact factor: 29.983

5.  Oral rivaroxaban for symptomatic venous thromboembolism.

Authors:  Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong
Journal:  N Engl J Med       Date:  2010-12-03       Impact factor: 91.245

Review 6.  Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis.

Authors:  Daniel Caldeira; Márcio Barra; Fausto J Pinto; Joaquim J Ferreira; João Costa
Journal:  J Neurol       Date:  2014-08-14       Impact factor: 4.849

7.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

8.  Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

Authors:  James J Ferguson; Robert M Califf; Elliott M Antman; Marc Cohen; Cindy L Grines; Shaun Goodman; Dean J Kereiakes; Anatoly Langer; Kenneth W Mahaffey; Christopher C Nessel; Paul W Armstrong; Alvaro Avezum; Phil Aylward; Richard C Becker; Luigi Biasucci; Steven Borzak; Jacques Col; Marty J Frey; Ed Fry; Dietrich C Gulba; Sema Guneri; Enrique Gurfinkel; Robert Harrington; Judith S Hochman; Neal S Kleiman; Martin B Leon; Jose Luis Lopez-Sendon; Carl J Pepine; Witold Ruzyllo; Steven R Steinhubl; Paul S Teirstein; Luis Toro-Figueroa; Harvey White
Journal:  JAMA       Date:  2004-07-07       Impact factor: 56.272

9.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

10.  Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases.

Authors:  Waltraud Pfeilschifter; Mario Abruscato; Susanne Hövelmann; Horst Baas
Journal:  Case Rep Neurol       Date:  2013-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.